Werewolf Therapeutics Inc... (HOWL)
Werewolf Therapeutics Statistics
Share Statistics
Werewolf Therapeutics has 44.83M shares outstanding. The number of shares has increased by 3.16% in one year.
| Shares Outstanding | 44.83M |
| Shares Change (YoY) | 3.16% |
| Shares Change (QoQ) | 0.59% |
| Owned by Institutions (%) | 64.45% |
| Shares Floating | 33.13M |
| Failed to Deliver (FTD) Shares | 474 |
| FTD / Avg. Volume | 0.18% |
Short Selling Information
The latest short interest is 2.26M, so 5.04% of the outstanding shares have been sold short.
| Short Interest | 2.26M |
| Short % of Shares Out | 5.04% |
| Short % of Float | 8.46% |
| Short Ratio (days to cover) | 7.57 |
Valuation Ratios
The PE ratio is -0.91 and the forward PE ratio is -0.6. Werewolf Therapeutics's PEG ratio is -0.02.
| PE Ratio | -0.91 |
| Forward PE | -0.6 |
| PS Ratio | 34.02 |
| Forward PS | 0.2 |
| PB Ratio | 0.87 |
| P/FCF Ratio | -1.14 |
| PEG Ratio | -0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Werewolf Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.45, with a Debt / Equity ratio of 0.51.
| Current Ratio | 7.45 |
| Quick Ratio | 7.45 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | -0.58 |
| Debt / FCF | -0.66 |
| Interest Coverage | -15.81 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $40.98K |
| Profits Per Employee | $-1.53M |
| Employee Count | 46 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -85.69% in the last 52 weeks. The beta is 0.48, so Werewolf Therapeutics's price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | -85.69% |
| 50-Day Moving Average | 1.02 |
| 200-Day Moving Average | 1.74 |
| Relative Strength Index (RSI) | 47.61 |
| Average Volume (20 Days) | 260.2K |
Income Statement
In the last 12 months, Werewolf Therapeutics had revenue of 1.89M and earned -70.52M in profits. Earnings per share was -1.63.
| Revenue | 1.89M |
| Gross Profit | 71K |
| Operating Income | -73.59M |
| Net Income | -70.52M |
| EBITDA | -64.05M |
| EBIT | -65.86M |
| Earnings Per Share (EPS) | -1.63 |
Balance Sheet
The company has 112.22M in cash and 37.09M in debt, giving a net cash position of 75.13M.
| Cash & Cash Equivalents | 112.22M |
| Total Debt | 37.09M |
| Net Cash | 75.13M |
| Retained Earnings | -414.59M |
| Total Assets | 126.93M |
| Working Capital | 97.89M |
Cash Flow
In the last 12 months, operating cash flow was -56.19M and capital expenditures -254K, giving a free cash flow of -56.44M.
| Operating Cash Flow | -56.19M |
| Capital Expenditures | -254K |
| Free Cash Flow | -56.44M |
| FCF Per Share | -1.3 |
Margins
Gross margin is 3.77%, with operating and profit margins of -3904.19% and -3740.85%.
| Gross Margin | 3.77% |
| Operating Margin | -3904.19% |
| Pretax Margin | -3740.85% |
| Profit Margin | -3740.85% |
| EBITDA Margin | -3397.61% |
| EBIT Margin | -3904.19% |
| FCF Margin | -2994.27% |
Dividends & Yields
HOWL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for HOWL is $8, which is 819.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 819.5% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -4.96 |
| Piotroski F-Score | 3 |